Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report)’s share price rose 24.6% on Wednesday . The stock traded as high as $1.14 and last traded at $1.06. 2,994,528 shares changed hands during mid-day trading, an increase of 138,215% from the average daily volume of 2,165 shares. The stock had previously closed at $0.8506.
Graybug Vision Price Performance
The company’s 50-day moving average price is $0.73 and its 200-day moving average price is $2.11. The company has a market cap of $1.67 million, a P/E ratio of -0.61 and a beta of 1.20.
Graybug Vision Company Profile
Graybug Vision, Inc is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. The company’s proprietary Depot Technology Platform is designed to deliver sustained-release formulations of biologically active agents directly to the back of the eye, with the goal of reducing treatment burden and improving patient outcomes. Graybug’s lead product candidate, GB-102, is a long-acting formulation of sunitinib malate being investigated for the treatment of wet age-related macular degeneration (wet AMD).
Featured Articles
- Five stocks we like better than Graybug Vision
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
- Why Palantir’s Google Cloud Deal Could Change the Debate
- AI’s Power Problem Is Turning Nuclear Stocks Into a Bigger Market Story
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
